Natera notifies availability of press release on Signatera Merkel cell carcinoma study in JAMA Dermatology
NTRA•Signatera study in JAMA Dermatology
Natera released a press release on a JAMA Dermatology study comparing Signatera MRD with AMERK in Merkel cell carcinoma surveillance.
- Head-to-head analysis in 169 patients showed Signatera was a stronger recurrence predictor than AMERK (HR difference 6.6; p < 0.001).
- Signatera sensitivity was 90% versus 55% for AMERK, with earlier detection in dual-positive cases (median lead time 5.1 months versus 2.1 months).
